Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer

Reuters09-29

<a href="https://laohu8.com/S/LSTA">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer

Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571338178?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571338178","market":"us","top_or_hot":-1,"title":"Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9FlkGt:1","article_id":"2571338178","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571338178","pubTimestamp":1759147242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma  cohort of its Phase 1/2a CENDIFOX trial . The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide , in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research  Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LSTA":"LISATA THERAPEUTICS INC","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Lisata Therapeutics宣布Certepetide治疗胰腺癌的CENDIFOX试验取得令人鼓舞的初步结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9,"NDAQ":0.9},"content_text":"Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer\n    \n\n        Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma (PDAC) cohort of its Phase 1/2a CENDIFOX trial (NCT05121038). The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide (CEND-1/LSTA1), in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535939-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571338178","isCrawlerRequest":true}